Inventiva reveals late breaker abstract from LEGEND Phase 2 trial on lanifibranor with empagliflozin in MASH at AASLD 2024

Daix, France, and Long Island City, New York, United States, October 21, 2024 – Inventiva, a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for treating metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH), has announced significant progress in their research. The company revealed that the findings from the Phase 2 LEGEND study, which evaluates the combination of lanifibranor and empagliflozin in patients with MASH and Type-2 Diabetes (T2D), have been accepted as a late breaker by the scientific committee of the 75th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024. This event will occur from November 15 to 19, 2024, in San Diego, California.

The abstract titled "Combination therapy of lanifibranor with empagliflozin: metabolic improvement in patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Type-2 Diabetes (T2D)" will be presented as a poster on November 18. The authors of this study include Michelle Lai, Onno Holleboom, Lucile Dzen, Philippe Huot-Marchand, Jean-Louis Junien, Pierre Broqua, Louis Griffel, Sanjay Patel, and Michael P. Cooreman.

Lanifibranor, Inventiva’s lead product candidate, is an oral small molecule designed to effect antifibrotic, anti-inflammatory, and beneficial vascular and metabolic changes. It functions by activating all three isoforms of the peroxisome proliferator-activated receptor (PPAR) – PPARα, PPARδ, and PPARγ. This balanced activation distinguishes lanifibranor from other PPAR agonists that typically target only one or two isoforms. Lanifibranor is the sole pan-PPAR agonist in clinical development for MASH/NASH treatment and has shown favorable tolerability in clinical and pre-clinical trials. The FDA has granted Fast Track and Breakthrough Therapy designations to lanifibranor for treating MASH/NASH.

Inventiva is a clinical-stage biopharmaceutical company specializing in oral small molecule therapies aimed at treating patients with MASH/NASH and other diseases with significant unmet needs. The company's expertise lies in targeting nuclear receptors, transcription factors, and epigenetic modulation. Currently, Inventiva is advancing one clinical candidate and has two preclinical programs in its pipeline. The company's flagship product candidate, lanifibranor, is undergoing a pivotal Phase III clinical trial, NATiV3, for treating adult MASH/NASH patients. Additionally, the pipeline includes odiparcil, intended for treating adult MPS VI patients. However, Inventiva has suspended clinical efforts for odiparcil to focus on lanifibranor’s development and is reviewing further development options for odiparcil. The company is also working on selecting a candidate for its Hippo signaling pathway program.

Inventiva's scientific team comprises around 90 individuals with deep expertise in biology, medicinal and computational chemistry, pharmacokinetics, pharmacology, and clinical development. The company owns an extensive library of about 240,000 pharmacologically relevant molecules, with approximately 60% being proprietary. Moreover, Inventiva has a wholly-owned research and development facility.

Inventiva is publicly listed on Euronext Paris (ticker: IVA, ISIN: FR0013233012) and the Nasdaq Global Market in the United States (ticker: IVA). The company’s commitment to advancing therapies for MASH/NASH and other significant medical conditions is well-recognized within the scientific community, underscoring the potential impact of its ongoing research and development efforts.